Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate vs placebo in children with osteogenesis imperfecta
2004-000485-13Phase 3Completed
- Sponsor
- Procter & Gamble
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteogenesis imperfecta (OI) comparing Risedronate with Placebo (2 arms). Primary endpoint: Percent change from baseline in lumbar spine BMD at Month 12. Started Feb 2006; status: completed.
02
Drugs
risedronate
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2004-000485-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000485-13.